Ebola in the DRC one year later – Boiling the frog?

International Journal of Infectious Diseases
August 2019 Volume 85, p1-214
https://www.ijidonline.com/issue/S1201-9712(19)X0011-9

 

Editorial
Ebola in the DRC one year later – Boiling the frog?
Susan McLellan, Mark G. Kortepeter, Nahid Bhadelia, Erica S. Shenoy, Lauren M. Sauer, Maria G. Frank, Theodore J. Cieslak
p212–213
Published online: July 19, 2019
… In summary, security concerns in DRC provide a significant barrier to outbreak assistance; however, maintaining the current level of international engagement is likely to allow the outbreak to continue to spread within DRC, and eventually to neighboring and in turn distant countries. This will not be the last outbreak of Ebola in the DRC or elsewhere. It is to our benefit to seek ways to demonstrate this is not another case of “helicopter” intervention, but a long-term commitment for humanitarian aid and to bolster the health care system overall in DRC and develop sustainable response strategies that can be deployed to other communicable disease outbreaks in the future.
A deliberate, thoughtful scale-up of involvement in support of and in collaboration with partners on the ground, including the WHO and DRC government would ensure a seamless effort that is responsive to the communities’ and partners’ needs and help tip the scales. Such a demonstration would go a long way in winning the hearts and minds and cooperation of the local population who are there for the long term.

Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease

International Journal of Infectious Diseases
August 2019 Volume 85, p1-214
https://www.ijidonline.com/issue/S1201-9712(19)X0011-9

 

Reviews
Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease
Philip S. Watson, Patricia L. Novy, Leonard R. Friedland
p22–27
Published online: May 15, 2019

N95 Respirators vs Medical Masks for Preventing Influenza Among Health Care PersonnelA Randomized Clinical Trial

JAMA
September 3, 2019, Vol 322, No. 9, Pages 795-900
http://jama.jamanetwork.com/issue.aspx

 

Original Investigation
N95 Respirators vs Medical Masks for Preventing Influenza Among Health Care PersonnelA Randomized Clinical Trial
Lewis J. Radonovich Jr, MD; Michael S. Simberkoff, MD; Mary T. Bessesen, MD; et al.
JAMA. 2019;322(9):824-833. doi:10.1001/jama.2019.11645
This cluster randomized clinical trial compares the effect of N95 respirators vs medical masks worn by health care personnel for prevention of workplace-acquired influenza and other viral respiratory infections in geographically diverse, high-exposure outpatient settings.

Harms From Uninformative Clinical Trials

JAMA
September 3, 2019, Vol 322, No. 9, Pages 795-900
http://jama.jamanetwork.com/issue.aspx

 

Viewpoint
Harms From Uninformative Clinical Trials
Deborah A. Zarin, MD; Steven N. Goodman, MD, MHS, PhD; Jonathan Kimmelman, PhD
JAMA. 2019;322(9):813-814. doi:10.1001/jama.2019.9892
This Viewpoint discusses key features of and incentives for randomized clinical trials (RCTs) that make many of them uninformative; reviews the challenges uninformative trials pose to ethics, science, and medical practice; and recommends what academic medical centers and funders can do to incentivize the conduct of RCTs that provide valid information that informs clinical practice.

Implications of Changing Public Charge Immigration Rules for Children Who Need Medical Care

JAMA Pediatrics
September 2019, Vol 173, No. 9, Pages 807-900
http://archpedi.jamanetwork.com/issue.aspx

 

Original Investigation
Implications of Changing Public Charge Immigration Rules for Children Who Need Medical Care
Leah Zallman, MD, MPH; Karen E. Finnegan, PhD; David U. Himmelstein, MD; et al.
online only
JAMA Pediatr. 2019;173(9):e191744. doi:10.1001/jamapediatrics.2019.1744
This cross-sectional study simulates the number, medical conditions, and care needs of children who are at risk of losing their current benefits, including Medicaid and Children’s Health Insurance Program and Supplemental Nutrition Assistance Program, after a proposed US federal rule change.

Assessing national governance of medicine promotion: an exploratory study in Ghana to trial a structured set of indicators

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 7 Sep2019]

 

Research
|   4 September 2019
Assessing national governance of medicine promotion: an exploratory study in Ghana to trial a structured set of indicators
Authors: Marcia McLean, Jillian Clare Kohler and Danny Edwards
Background
Two billion people worldwide, predominantly in low- and middle-income countries, cannot consistently access required essential medications, thus affecting their ability to attain optimal health outcomes. Access to appropriate medicines may be compromised due to issues involving cost, availability, quality, and prescribing practices, and system-wide factors such as a lack of transparency and accountability. Pharmaceutical promotional practices impact many of these issues, thus influencing the use of appropriate medicines,. Good governance is ultimately the responsibility of national governments through strong health systems with transparent and accountable practices that facilitate appropriate medicine use. We designed a structured set of indicators, based on existing tools, to assess the strength of the national governance of pharmaceutical promotion. In this exploratory study, we trialed the indicators in Ghana.

Blinding Me With Science: Complementary “Head” and “Heart” Messages Are Needed to Counter Rising Vaccine Hesitancy

Journal of Public Health Management & Practice
September/October 2019 – Volume 25 – Issue 5
https://journals.lww.com/jphmp/pages/currenttoc.aspx

 

State of Public Health
Blinding Me With Science: Complementary “Head” and “Heart” Messages Are Needed to Counter Rising Vaccine Hesitancy
Fraser, Michael R.
Journal of Public Health Management and Practice. 25(5):511-514, September/October 2019.

What is the prospect of a safe and effective dengue vaccine for travellers?

Journal of Travel Medicine
Volume 26, Issue 6, 2019
https://academic.oup.com/jtm/issue/26/6

 

Editor’s Choice
What is the prospect of a safe and effective dengue vaccine for travellers?
Anna P Durbin, MD, Duane J Gubler, ScD
Journal of Travel Medicine, Volume 26, Issue 6, 2019, tay153, https://doi.org/10.1093/jtm/tay153
Dengue affects hundreds of millions of persons each year and is a risk for travellers to dengue-endemic regions. The first licensed dengue vaccine is approved for use only in persons who are known to have had previous dengue infection, limiting its potential for use in travellers. Two other dengue vaccines are currently in Phase 3 clinical trials, with preliminary efficacy results expected soon. These vaccines differ from the currently licensed vaccine and, should they demonstrate efficacy, may offer the possibility of a dengue vaccine for travellers.

Addressing vaccine hesitancy in travellers: The CARD™ System

Journal of Travel Medicine
Volume 26, Issue 6, 2019
https://academic.oup.com/jtm/issue/26/6

 

Addressing vaccine hesitancy in travellers: The CARD™ System
Anna Taddio, PhD, Noni MacDonald, MD
Journal of Travel Medicine, Volume 26, Issue 6, 2019, taz056, https://doi.org/10.1093/jtm/taz056
Current vaccination programs do not fully incorporate client-centred care in the delivery of vaccinations; hence, do not address vaccination hesitancy. This article provides a summary of a novel client-centred approach to vaccinations to improve the vaccination experience and promote vaccination.

Yellow fever vaccination for immunocompromised travellers: unjustified vaccination hesitancy?

Journal of Travel Medicine
Volume 26, Issue 6, 2019
https://academic.oup.com/jtm/issue/26/6

 

Perspectives
Yellow fever vaccination for immunocompromised travellers: unjustified vaccination hesitancy?
Wesley de Jong, MD, Rob A de Man, MD PhD, Virgil A S H Dalm, MD PhD, Chantal B E M Reusken, PhD, Marco Goeijenbier, MD PhD
Journal of Travel Medicine, Volume 26, Issue 6, 2019, taz015, https://doi.org/10.1093/jtm/taz015
Improved quality of life in immunocompromised patients opens travel opportunities, but administering the yellow fever (YF) vaccine is often contraindicated. We advocate re-evaluating this position for immunocompromised patients who travel frequently or who are migrating to regions in which YF is endemic.

Seroprotection rates of vaccine-preventable diseases among newly arrived Eritrean asylum seekers in Switzerland: a cross-sectional study

Journal of Travel Medicine
Volume 26, Issue 6, 2019
https://academic.oup.com/jtm/issue/26/6

Seroprotection rates of vaccine-preventable diseases among newly arrived Eritrean asylum seekers in Switzerland: a cross-sectional study
Cornelia Staehelin, MD, MIH, Afona Chernet, PhD, Véronique Sydow, MD, Rein J Piso, MD, Franziska Suter-Riniker, PhD

 

Measles and the 2019 Hajj: the risk of magnifying the global measles surge

Journal of Travel Medicine
Volume 26, Issue 6, 2019
https://academic.oup.com/jtm/issue/26/6

 

Rapid Communication
Measles and the 2019 Hajj: the risk of magnifying the global measles surge
Ziad A Memish, MD, FRCPC, FRCPE, FRCPL, FACP, FFPH, Anas A Khan, MD, Shahul Ebrahim, MD, MSc, PhD
Journal of Travel Medicine, Volume 26, Issue 6, 2019, taz041, https://doi.org/10.1093/jtm/taz041
The projected linear increases in Muslim pilgrims for Hajj and Umra to Saudi Arabia from current 7 million to 30 million by 2030 will increase the density of pilgrims and the potential for infectious disease transmission. Because pilgrims originate from over 180 countries, the Hajj and Umrah pilgrimage can further compound the ongoing measles outbreaks. Vaccine hesitancy among Muslim populations should receive special attention in addition to general measles control efforts.

 

The rise in travel-associated measles infections—GeoSentinel, 2015–2019

Journal of Travel Medicine
Volume 26, Issue 6, 2019
https://academic.oup.com/jtm/issue/26/6

 

The rise in travel-associated measles infections—GeoSentinel, 2015–2019
Kristina M Angelo, Michael Libman, Philippe Gautret, Elizabeth Barnett, Martin P Grobusch
Journal of Travel Medicine, Volume 26, Issue 6, 2019, taz046, https://doi.org/10.1093/jtm/taz046
The global threat of measles in recent years affects international travelers, and is acquired in both endemic and outbreak settings. The number of measles cases reported to GeoSentinel has risen each year since 2015 and demonstrates a high median age, short travel duration, and low measles

 

Yellow fever and Hajj 2019: from airline introduction of mosquitoes to expanding geography of transmission and vaccination challenges

Journal of Travel Medicine
Volume 26, Issue 6, 2019
https://academic.oup.com/jtm/issue/26/6

 

Yellow fever and Hajj 2019: from airline introduction of mosquitoes to expanding geography of transmission and vaccination challenges
Shahul H Ebrahim, MD, Ziad A Memish, MD
Journal of Travel Medicine, Volume 26, Issue 6, 2019, taz051, https://doi.org/10.1093/jtm/taz051
Yellow fever epidemiology is changing with large-scale epidemics in Africa, increased risk of urban outbreaks in Latin America, and spread to Asia. Therefore, in addition to the changing epidemiology, mosquito resurgence, and urbanization of yellow fever, the Hajj 2019 presents another challenge to the well-structured global strategy for YF Control.

 

Measles and the 2019 Hajj: risk of international transmission

Journal of Travel Medicine
Volume 26, Issue 6, 2019
https://academic.oup.com/jtm/issue/26/6

Measles and the 2019 Hajj: risk of international transmission
Sakshi Shetty, Maya Murmann, Ashleigh R Tuite, Alexander G Watts, Isaac Bogoch
Journal of Travel Medicine, Volume 26, Issue 6, 2019, taz058, https://doi.org/10.1093/jtm/taz058
The current global increase in measles cases is associated with a small but non-negligible risk of an infected pilgrim arriving at the 2019 Hajj. Since even a single imported case can cause an outbreak in vulnerable populations, Saudi Arabia and countries with returning pilgrims should be alert for measles cases.

 

Insights and challenges in tuberculosis vaccine development

Lancet Respiratory Medicine
Sep 2019 Volume 7 Number 9 p721-826, e26-e28
http://www.thelancet.com/journals/lanres/issue/current

 

Series
Tuberculosis 2019
Insights and challenges in tuberculosis vaccine development
Helen McShane
Summary
Tuberculosis kills more people than any other pathogen and the need for a universally effective vaccine has never been greater. An effective vaccine will be a key tool in achieving the targets set by WHO in the End TB Strategy. Tuberculosis vaccine development is difficult and slow. Substantial progress has been made in research and development of tuberculosis vaccines in the past 20 years, and two clinical trial results from 2018 provide reason for optimism. However, many challenges to the successful licensure and deployment of an effective tuberculosis vaccine remain. The development of new tools for vaccine evaluation might facilitate these processes, and continued collaborative working and sustained funding will be essential.

The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis

Lancet Respiratory Medicine
Sep 2019 Volume 7 Number 9 p721-826, e26-e28
http://www.thelancet.com/journals/lanres/issue/current

 

Commission Update
The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis
Keertan Dheda, Tawanda Gumbo,Gary Maartens, Kelly E Dooley, Megan Murray, Jennifer Furin,
Edward A Nardell, Robin M Warren, on behalf of The Lancet Respiratory Medicine drug-resistant tuberculosis Commission group
Summary
The Lancet Respiratory Medicine Commission on drug-resistant tuberculosis was published in 2017, which comprehensively reviewed and provided recommendations on various aspects of the disease. Several key new developments regarding drug-resistant tuberculosis are outlined in this Commission Update. The WHO guidelines on treating drug-resistant tuberculosis were updated in 2019 with a reclassification of second line anti-tuberculosis drugs. An injection-free MDR tuberculosis treatment regimen is now recommended. Over the past 3 years, advances in treatment include the recognition of the safety and mortality benefit of bedaquiline, the finding that the 9–11 month injectable-based ‘Bangladesh’ regimen was non-inferior to longer regimens, and promising interim results of a novel 6 month 3-drug regimen (bedaquiline, pretomanid, and linezolid). Studies of explanted lungs from patients with drug-resistant tuberculosis have shown substantial drug-specific gradients across pulmonary cavities, suggesting that alternative dosing and drug delivery strategies are needed to reduce functional monotherapy at the site of disease. Several controversies are discussed including the optimal route of drug administration, optimal number of drugs constituting a regimen, selection of individual drugs for a regimen, duration of the regimen, and minimal desirable standards of antibiotic stewardship. Newer rapid nucleic acid amplification test platforms, including point-of-care systems that facilitate active case-finding, are discussed. The rapid diagnosis of resistance to other drugs, (notably fluoroquinolones), and detection of resistance by targeted or whole genome sequencing will probably change the diagnostic landscape in the near future.

Mendel for the modern era

Nature Genetics
Volume 51 Issue 9, September 2019
https://www.nature.com/ng/volumes/51/issues/9

 

Editorial | 02 September 2019
Mendel for the modern era
The genome of the model genetic organism Pisum sativum, or pea plant, links nineteenth-century genetics to twenty-first-century genomics, serving as a symbol of how far the genetics field has developed and how greatly technologies have advanced. Almost every student’s introduction to genetics currently involves learning Mendel’s laws; we envision that genomics and genome sequencing will become just as foundational in the education of future geneticists.

A reference genome for pea provides insight into legume genome evolution

Nature Genetics
Volume 51 Issue 9, September 2019
https://www.nature.com/ng/volumes/51/issues/9

 

Article | 02 September 2019 | Open Access
A reference genome for pea provides insight into legume genome evolution
The first annotated chromosome-level reference genome assembly for pea, Gregor Mendel’s original genetic model, provides insights into legume genome evolution and the molecular basis of agricultural traits for pea improvement.
Jonathan Kreplak, Mohammed-Amin Madoui[…] & Judith Burstin

Toppling the Ethical Balance — Health Care Refusal and the Trump Administration

New England Journal of Medicine
September 5, 2019 Vol. 381 No. 10
http://www.nejm.org/toc/nejm/medical-journal

 

Perspective
Toppling the Ethical Balance — Health Care Refusal and the Trump Administration
E. Sepper
A new rule from the U.S. Department of Health and Human Services creates a wide-ranging right to refuse to provide health care services. If it goes into effect, patient health and professional practice are likely to suffer.

Early Childhood Vaccination Status of Preterm Infants

Pediatrics
September 2019, VOLUME 144 / ISSUE 3
https://pediatrics.aappublications.org/content/144/3?current-issue=y

 

Articles
Early Childhood Vaccination Status of Preterm Infants
Annika M. Hofstetter, Elizabeth N. Jacobson, M. Patricia deHart, Janet A. Englund
Pediatrics Sep 2019, 144 (3) e20183520; DOI: 10.1542/peds.2018-3520
In this retrospective study, we used EHR and immunization information system data to compare early childhood vaccination of preterm and term/post term infants born between 2008 and 2013.

Transmission of Vaccine-Strain Varicella-Zoster Virus: A Systematic Review

Pediatrics
September 2019, VOLUME 144 / ISSUE 3
https://pediatrics.aappublications.org/content/144/3?current-issue=y

 

Review Articles
Transmission of Vaccine-Strain Varicella-Zoster Virus: A Systematic Review
Mona Marin, Jessica Leung, Anne A. Gershon
Pediatrics Sep 2019, 144 (3) e20191305; DOI: 10.1542/peds.2019-1305
We reviewed the published experience with the use of live VZV vaccines to assess characteristics of secondary transmission of the vaccine-strain virus.

Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions

PharmacoEconomics
Volume 37, Issue 9, September 2019
https://link.springer.com/journal/40273/37/9

 

Systematic Review
Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions
Marina Treskova, Stefan M. Scholz, Alexander Kuhlmann

Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 7 Sep2019)

 

Collection Review
Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance
Christian Lienhardt, Andrew A. Vernon, Marco Cavaleri, Sumati Nambiar, Payam Nahid
| published 06 Sep 2019 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1002915

Social network interventions for health behaviours and outcomes: A systematic review and meta-analysis

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 7 Sep2019)

 

Research Article
Social network interventions for health behaviours and outcomes: A systematic review and meta-analysis
There has been a growing interest in understanding the effects of social networks on health-related behaviour, with a particular backdrop being the emerging prominence of complexity or systems science in public health. Social network interventions specifically use or alter the characteristics of social networks to generate, accelerate, or maintain health behaviours. We conducted a systematic review and meta-analysis to investigate health behaviour outcomes of social network interventions.
Ruth F. Hunter, Kayla de la Haye, Jennifer M. Murray, Jennifer Badham, Thomas W. Valente, Mike Clarke, Frank Kee
| published 03 Sep 2019 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1002890

Vaccination timeliness and associated factors among preterm infants at a tertiary hospital in Uganda

PLoS One
http://www.plosone.org/
[Accessed 7 Sep2019]

 

Research Article
Vaccination timeliness and associated factors among preterm infants at a tertiary hospital in Uganda
Irene Nakatudde, Joseph Rujumba, Flavia Namiiro, Ali Sam, Jamir Mugalu, Philippa Musoke
Research Article | published 06 Sep 2019 PLOS ONE
https://doi.org/10.1371/journal.pone.0221902

Burden of influenza-associated respiratory hospitalizations in the Americas, 2010–2015

PLoS One
http://www.plosone.org/
[Accessed 7 Sep2019]

 

Burden of influenza-associated respiratory hospitalizations in the Americas, 2010–2015
Rakhee S. Palekar, Melissa A. Rolfes, C. Sofia Arriola, Belsy O. Acosta, Patricia Alberto Guidos, Xiomara Badilla Vargas, Christina Bancej, Juliana Barbosa Ramirez, Elsa Baumeister, Alfredo Bruno, Maria Agüeda Cabello, Jufu Chen, Paula Couto, Francisco J. De Paula Junior, Rodrigo Fasce, Walquiria Ferreira de Almeida, Victor E. Fiesta Solorzano, Carlos Flores Ramírez, Natalia Goñi, Yadira Isaza de Moltó, Jenny Lara, Diana C. Malo, José L. Medina Osis, Homer Mejía, Lourdes Moreno Castillo, Desiree Mustaquim, Andrea Nwosu, Jenny Ojeda, Antonio Paredes Samoya, Paola A. Pulido, Hector M. Ramos Hernandez, Rudvelinda Rivera Lopez, Angel Rodriguez, Myriam Saboui, Hilda Salazar Bolanos, Adrián Santoro, Jose Eduardo Silvera, Paulina Sosa, Viviana Sotomayor, Lourdes Suarez, Marta Von Horoch, Eduardo Azziz-Baumgartner
Research Article | published 06 Sep 2019 PLOS ONE
https://doi.org/10.1371/journal.pone.0221479

Delayed second dose of oral cholera vaccine administered before high-risk period for cholera transmission: Cholera control strategy in Lusaka, 2016

PLoS One
http://www.plosone.org/
[Accessed 7 Sep2019]

 

Delayed second dose of oral cholera vaccine administered before high-risk period for cholera transmission: Cholera control strategy in Lusaka, 2016
Eva Ferreras, Belem Matapo, Elizabeth Chizema-Kawesha, Orbrie Chewe, Hannah Mzyece, Alexandre Blake, Loveness Moonde, Gideon Zulu, Marc Poncin, Nyambe Sinyange, Nancy Kasese-Chanda, Caroline Phiri, Kennedy Malama, Victor Mukonka, Sandra Cohuet, Florent Uzzeni, Iza Ciglenecki, M. Carolina Danovaro-Holliday, Francisco J. Luquero, Lorenzo Pezzoli
Research Article | published 30 Aug 2019 PLOS ONE
https://doi.org/10.1371/journal.pone.0219040
Abstract
Background
In April 2016, an emergency vaccination campaign using one dose of Oral Cholera Vaccine (OCV) was organized in response to a cholera outbreak that started in Lusaka in February 2016. In December 2016, a second round of vaccination was conducted, with the objective of increasing the duration of protection, before the high-risk period for cholera transmission. We assessed vaccination coverage for the first and second rounds of the OCV campaign.
Methods
Vaccination coverage was estimated after each round from a sample selected from targeted-areas for vaccination using a cross-sectional survey in to establish the vaccination status of the individuals recruited. The study population included all individuals older than 12 months residing in the areas targeted for vaccination. We interviewed 505 randomly selected individuals after the first round and 442 after the second round. Vaccination status was ascertained either by vaccination card or verbal reporting. Households were selected using spatial random sampling.
Results
The vaccination coverage with two doses was 58.1% (25/43; 95%CI: 42.1–72.9) in children 1–5 years old, 59.5% (69/116; 95%CI: 49.9–68.5) in children 5–15 years old and 19.9% (56/281; 95%CI: 15.4–25.1) in adults above 15 years old. The overall dropout rate was 10.9% (95%CI: 8.1–14.1). Overall, 69.9% (n = 309/442; 95%CI: 65.4–74.1) reported to have received at least one OCV dose.
Conclusions
The areas at highest risk of suffering cholera outbreaks were targeted for vaccination obtaining relatively high vaccine coverage after each round. However, the long delay between doses in areas subject to considerable population movement resulted in many individuals receiving only one OCV dose. Additional vaccination campaigns may be required to sustain protection over time in case of persistence of risk. Further evidence is needed to establish a maximum optimal interval time of a delayed second dose and variations in different settings.

Completion of the Human Papillomavirus Vaccination Series Among Adolescent Users and Nonusers of School-Based Health Centers

Public Health Reports
Volume 134 Issue 5, September/October 2019
https://journals.sagepub.com/toc/phrg/134/5

 

Research
Completion of the Human Papillomavirus Vaccination Series Among Adolescent Users and Nonusers of School-Based Health Centers
Meaghan S. Munn, MPH, Meagan Kay, DVM, MPVM, Libby C. Page, MPH, Jeffrey S. Duchin, MD
First Published August 12, 2019; pp. 559–566

Initial care for migrants in Chile: status of a primary health care initiative after one year of implementation

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
http://www.paho.org/journal/index.php?option=com_content&view=featured&Itemid=101

 

6 Sep 2019
Initial care for migrants in Chile: status of a primary health care initiative after one year of implementation
Original research | Spanish |

Controversy over dengue vaccine risk

Science
06 September 2019 Vol 365, Issue 6457
http://www.sciencemag.org/current.dtl

 

In Depth
Controversy over dengue vaccine risk
By Jon Cohen
Science06 Sep 2019 : 961-962 Restricted Access
All immunized Filipino kids should be tested, some say.
Summary
Shortly after Dengvaxia came to market in 2015, the Philippines launched a massive campaign to immunize children against the dreaded diseases. After about 1 million children were vaccinated, Sanofi Pasteur, the Paris-based maker of the product, revealed that ongoing clinical trials had found a rare, dangerous complication. Four distinct variants of dengue infect humans. In a well-known phenomenon, people infected with one strain who become infected with a second one become vulnerable to severe dengue, which can cause life-threatening shock and hemorrhagic fever. The vaccine, when given to children who had never been infected with dengue, primes some for that rare phenomenon of severe disease. Now, some researchers are calling for studies that would test the vaccinated children and identify the ones most at risk. They contend that if parents knew their children were at increased risk of severe disease, they could more aggressively seek care if they suspected dengue. This also might alleviate confusion for some parents who have blamed the vaccine for the death of their children. But no one has sponsored the study yet.

Awareness and attitude towards human papillomavirus and its vaccine among females with and without daughter(s) who participated in cervical cancer screening in Shenzhen, China

Tropical Medicine & International Health
Volume 24, Issue 9 Pages: i-iv, 1031-1137 September 2019
https://onlinelibrary.wiley.com/toc/13653156/current

 

Original Research Papers
Awareness and attitude towards human papillomavirus and its vaccine among females with and without daughter(s) who participated in cervical cancer screening in Shenzhen, China
Wei Lin, Yueyun Wang, Zhihua Liu, Bin Chen, Shixin Yuan, Bo Wu, Lin Gong
Pages: 1054-1063
First Published: 02 July 2019

Introducing rotavirus vaccine in the Universal Immunization Programme in India: From evidence to policy to implementation

Vaccine
Volume 37, Issue 39 Pages 5807-5908 (16 September 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/39

 

Review article Abstract only
Introducing rotavirus vaccine in the Universal Immunization Programme in India: From evidence to policy to implementation
Akash Malik, Pradeep Haldar, Arindam Ray, Anita Shet, … Rakesh Kumar
Pages 5817-5824

Timeliness and factors associated with rotavirus vaccine uptake among Australian Aboriginal and non-Aboriginal children: A record linkage cohort study

Vaccine
Volume 37, Issue 39 Pages 5807-5908 (16 September 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/39

 

Review article Abstract only
Timeliness and factors associated with rotavirus vaccine uptake among Australian Aboriginal and non-Aboriginal children: A record linkage cohort study
Parveen Fathima, Heather F. Gidding, Thomas L. Snelling, Peter B. McIntyre, … Hannah C. Moore
Pages 5835-5843
Abstract
Objectives
Rotavirus vaccines (RV), included in Australia’s National Immunisation Program from mid-July 2007, are unique in strict time limits for administration. Here, we report on timeliness of RV uptake, compare cumulative RV coverage to age 12 months with DTPa, and assess factors associated with receipt of RV among Aboriginal and non-Aboriginal children.
Methods
Birth records for 681,456 children born in two Australian states in 2007–2012 were probabilistically linked to national immunisation records. We assessed on-time coverage (defined as receipt of vaccine dose between 4 days prior to scheduled date and the recommended upper limit) for RV and compared this to diphtheria-tetanus-pertussis (DTPa) vaccine. Logistic regression modelling was used to assess independent determinants of receipt of RV.
Results
Compared to non-Aboriginal infants, on-time RV coverage was lower for all doses among Aboriginal infants. Post the upper age limit of RV dose2, DTPa dose2 coverage increased by 9–16% to ≥90%, whereas RV coverage remained around 77% (Aboriginal) and 85% (non-Aboriginal). Compared to first-born children, the adjusted odds of receiving ≥1 RV dose if born to a mother with ≥3 previous births was 0.30 (95%CI: 0.27–0.34) among Aboriginal, and 0.53 (95%CI: 0.51–0.55) among non-Aboriginal children. Prematurity (<33 weeks), low birthweight (<1500 g), maternal age <20 years, maternal smoking during pregnancy and living in a disadvantaged area were independently associated with decreased vaccine uptake.
Conclusions
Aboriginal children are at greater risk of rotavirus disease than non-Aboriginal children and delayed vaccine receipt is substantially higher. Although specific programs targeting groups at risk of delayed vaccination might improve RV coverage, relaxation of upper age restrictions is most readily implementable, and its overall risk-benefit should be evaluated.

Feasibility of case-control and test-negative designs to evaluate dengue vaccine effectiveness in Malaysia

Vaccine
Volume 37, Issue 39 Pages 5807-5908 (16 September 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/39

 

Research article Open access
Feasibility of case-control and test-negative designs to evaluate dengue vaccine effectiveness in Malaysia
Joshua Nealon, Wei-Yin Lim, Annick Moureau, Sharon Linus Lojikip, … Amar-Singh HSS
Pages 5891-5898

Feasibility of case-control and test-negative designs to evaluate dengue vaccine effectiveness in Malaysia

Vaccine
Volume 37, Issue 39 Pages 5807-5908 (16 September 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/39

 

Research article Open access
Feasibility of case-control and test-negative designs to evaluate dengue vaccine effectiveness in Malaysia
Joshua Nealon, Wei-Yin Lim, Annick Moureau, Sharon Linus Lojikip, … Amar-Singh HSS
Pages 5891-5898

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

Nature Immunology
Published: 02 September 2019
Comment
Vaccine hesitancy and coercion: all eyes on France
JK Ward, P Peretti-Watel, A Bocquier, V Seror, P Verger –
With record levels of vaccine hesitancy and one of the most drastic reinforcements of vaccine mandates in recent years, there is much to learn from the French experience.

Media/Policy Watch

Media/Policy Watch
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.
We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

 

ABC News – Australia
https://www.abc.net.au/news/
Accessed 7 Sep2019
Politics
‘No jab, no pay’ threat prompts an extra 174,000 children to be vaccinated in one year
By political reporter Matthew Doran
Posted 31 Aug 2019, 8:55pm
A threat to cut family tax benefits for Australians who did not vaccinate their children has resulted in an increase of 174,000 children being immunised over the last year.

 

The Atlantic
http://www.theatlantic.com/magazine/
Accessed 7 Sep2019
[No new, unique, relevant content]

 

BBC
http://www.bbc.co.uk/
Accessed 7 Sep2019
[No new, unique, relevant content]

 

The Economist
http://www.economist.com/
Accessed 7 Sep2019
[No new, unique, relevant content]

 

The Express Tribune – Pakistan
https://tribune.com.pk/
Accessed 7 Sep2019
Pakistan
With no refusal cases reported 7.1m children vaccinated in fresh polio drive
Published: August 30, 201
ISLAMABAD  : Around 7.1 million children in 46 districts of the country were administered polio drops in the recent vaccination campaign, according to the government figures.
“The recent campaign was successful,” read a statement issued by the Pakistan Polio Programme.
“No news of torture or verbal altercations in any part of the country was received.”…

 

Financial Times
http://www.ft.com/home/uk
Accessed 7 Sep2019
[No new, unique, relevant content]

 

Forbes
http://www.forbes.com/
Accessed 7 Sep2019
[No new, unique, relevant content]

 

Foreign Affairs
http://www.foreignaffairs.com/
Accessed 7 Sep2019
[No new, unique, relevant content]

Foreign Policy
http://foreignpolicy.com/
Accessed 7 Sep2019
[No new, unique, relevant content]

 

The Guardian
http://www.guardiannews.com/
Accessed 7 Sep2019
Vaccines and immunisation
Facebook to direct vaccine searches to public health pages
Facebook moves to stem spread of misinformation online about side-effects of immunisations
Sarah Boseley Health editor
Wed 4 Sep 2019 11.00 EDT
Facebook is to take a stand against vaccine denial by directing people searching for information or using vaccine hashtags to web pages set up by public health bodies.
People who access Facebook and Instagram pages and groups that discuss vaccines, as well as those searching or using relevant hashtags, will see an educational module about vaccine safety. Links will take them to a page provided by the Centers for Disease Control and Prevention (CDC) in the United States and to the World Health Organization elsewhere in the world…

 

New Yorker
http://www.newyorker.com/
Accessed 7 Sep2019
[No new, unique, relevant content]

 

New York Times
http://www.nytimes.com/
Accessed 7 Sep2019
Asia Pacific
WHO Welcomes Facebook Pledge to Curb Anti-Vaccine Misinformation
The World Health Organization said on Thursday it welcomed a commitment by Facebook that it would direct users seeking vaccine information on its Instagram, Facebook Search, Groups and other forums towards facts, not misinformation.
By Reuters

Africa
Former Congo Health Minister Questioned Over Ebola Spending
Sept. 2
Democratic Republic of Congo’s former health minister has been questioned by police over his management of funds in the country’s response to the Ebola epidemic, his lawyers said on Monday.
By Reuters

 

STAT
https://www.statnews.com/
Accessed 7 Sep2019
Health
With new grants, Gates Foundation takes an early step toward a universal flu vaccine
By Helen Branswell
August 29, 2019

Health
Federal rules threaten to discourage undocumented immigrants from vaccinating children
By Helen Branswell
August 26, 2019

 

Washington Post
http://www.washingtonpost.com/
Accessed 7 Sep2019
California lawmaker, governor reach deal on vaccine bill
Don Thompson | AP · National · Sep 6, 2019

Think Tanks et al

Think Tanks et al

Brookings
http://www.brookings.edu/
Accessed 7 Sep2019
[No new relevant content]

 

Center for Global Development
http://www.cgdev.org/page/press-center
[No new relevant content]

 

CSIS
https://www.csis.org/
Accessed 7 Sep2019
[No new relevant content]

 

Council on Foreign Relations
http://www.cfr.org/
Accessed 7 Sep2019
[No new relevant content]

 

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 7 Sep2019
[No new relevant content]

Vaccines and Global Health: The Week in Review :: 31 August 2019

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

 pdf version A pdf of the current issue is available here: Vaccines and Global Health_The Week in Review_31 Aug 2019

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

Gavi sets ambitious goal to immunise 300 million people by 2025, leaving no one behind 

Milestones :: Perspectives :: Research

Gavi sets ambitious goal to immunise 300 million people by 2025, leaving no one behind 
Yokohama/Geneva, 30 August 2019 – Gavi, the Vaccine Alliance has called on donors to back plans to immunise an additional 300 million children, saving up to eight million lives, in developing countries between 2021 and 2025, launching a fundraising drive of at least US$ 7.4 billion. A total of US$ 3.6 billion will be invested by developing country governments in their own vaccine programmes over the period, up from US$ 1.6 billion in 2016-2020.

The Investment Opportunity sets out how Gavi will provide the most comprehensive and cost-effective preventive health package in history. In Gavi’s first phase, beginning in 2000, it supported six basic vaccines; by 2025 this will rise to 18, including new support for inactivated polio vaccine (IPV), rabies and multivalent meningococcal vaccines, as well as funding for an Ebola vaccine stockpile once it is prequalified by the WHO. In its next phase the Vaccine Alliance will protect children against childhood diseases, adolescents against cervical cancer through the scaling up of human papillomavirus (HPV) vaccine support, and the world against deadly outbreaks of Ebola, cholera, yellow fever and meningitis through support for vaccine stockpiles.

The 2021-25 Investment Opportunity was launched at a special event at the Seventh Tokyo International Conference on African Development (TICAD) in Yokohama co-hosted by the Japanese government, which has supported Gavi with around US$ 150 million since 2011. Access to vaccination was also included in the Osaka G20 Leaders’ Declaration in June. TICAD 7 has brought together representatives of African countries, international organisations, development partners, private companies, civil society and others under the theme of ‘advancing Africa’s development through people, technology and innovation’…

European Region loses ground in effort to eliminate measles

Milestones :: Perspectives :: Research

 

European Region loses ground in effort to eliminate measles
Press release, WHO Europe
Copenhagen 29 August 2019
Following several years of steady progress toward elimination of measles in the WHO European Region, the number of countries having achieved or sustained elimination of the disease has declined. This was the conclusion of the European Regional Verification Commission for Measles and Rubella Elimination (RVC) based on an assessment of annual status updates for 2018 submitted by the 53 Member States of the Region.

 

The RVC determined that for the first time since the verification process began in the Region in 2012, 4 countries (Albania, Czechia, Greece and the United Kingdom) lost their measles elimination status.

“Re-establishment of measles transmission is concerning. If high immunization coverage is not achieved and sustained in every community, both children and adults will suffer unnecessarily and some will tragically die,” says Dr Günter Pfaff, Chair of the RVC.

The RVC was, on the other hand, pleased to conclude that Austria and Switzerland attained elimination status, having demonstrated the interruption of endemic transmission for at least 36 months.

For the Region as a whole, as of the end of 2018, 35 countries are considered to have achieved or sustained measles elimination (compared to 37 for 2017), 2 have interrupted the endemic transmission of measles (for 12–35 months), 12 remain endemic for measles and 4 that had previously eliminated the disease have re-established measles transmission.

The surge in cases that began in 2018 has continued into 2019, with approximately 90 000 cases reported for the first half of the year. This is already more than that recorded for the whole of 2018 (84,462)…

Gavi and Japanese growth equity fund collaborate to support innovative startups for immunisation 

Milestones :: Perspectives :: Research

 

Gavi and Japanese growth equity fund collaborate to support innovative startups for immunisation 
:: Vaccine Alliance launches US$ 7.4 billion fundraising drive to deliver highest return on investment to date offering broad protection against 18 diseases, saving up to eight million lives from 2021-25
:: Developing countries set to make largest investment in their own vaccine programmes in history, more than doubling the amount invested in the 2016-2020 period
:: Sustained investment needed to secure prosperity for the next generation, prevent resurgence of diseases and protect from frequent outbreaks made worse by climate change, urbanisation and conflicts

Yokohama, 28 August 2019 – Gavi, the Vaccine Alliance and Asia Africa Investment and Consulting (AAIC), a Japanese growth equity fund based in Singapore, have agreed to a collaboration that will help companies offering innovations to improve the delivery and availability of vaccines in developing countries. Gavi and AAIC signed the agreement at the Seventh Tokyo International Conference on African Development (TICAD), where Gavi is unveiling its 2021 to 2025 Investment Opportunity.

AAIC will provide funding of up to US$ 3 million for two years to companies that AAIC identifies through Gavi’s accelerator programme, Innovation for Uptake, Scale and Equity in Immunisation, or INFUSE. The funding from AAIC will focus on INFUSE finalists, known as Pacesetters, that are supporting early- and growth-stage health care companies operating in Africa to scale new cost-effective immunisation products and services…

Pinterest takes the right step toward curbing misinformation on vaccines

Milestones :: Perspectives :: Research

 

Opinion
Pinterest takes the right step toward curbing misinformation on vaccines
Washington Post
The Post’s View by Editorial Board
August 30 at 6:04 PM
HOW TO explain that one of the most effective medical innovations of all time is experiencing a crisis of confidence? That’s the situation with vaccines, which save millions of lives every year and especially help children fight disease.

A tide of “vaccine hesitancy,” reluctance to get inoculated because of unfounded fears and misinformation, is rising in the United States and throughout the world. The World Health Organization has identified vaccine hesitancy as one of the 10 most urgent public health challenges of this year.

The WHO director-general, Tedros Adhanom Ghebreyesus, pointed out recently that 20 million children worldwide simply lack access to vaccines because of war, weak primary health-care systems, poverty or unstable governments. But hesitancy among those who do have access is often the result of misinformation on social media, which can spread quickly.

For example, last spring, panic spread among parents in Pakistan because of a scaremongering video on Twitter that showed children seemingly collapsing after getting an expired vaccine. The video was obviously fake, but the panic was not, and it forced the suspension of a national immunization campaign.

Social media has also been responsible for spreading misinformation about vaccines for measles, a highly contagious illness that can have serious complications. So far this year in the United States, there have been 1,215 individual cases of measles, mostly unvaccinated individuals, the highest number of cases since 1992.

Last year, Pinterest, the social media platform, disabled search for terms such as “vaccines” or “cancer cure” because it realized the results were filled with misinformation. The platform says it discovered that, online, “anti-vaccine content is contagious” — it spreads quickly because it is more accessible, more visually compelling and more widely spread than scientific data.

Now, the platform has taken a laudable step toward changing this dynamic. On Aug. 28, Pinterest announced that it will provide information from only leading public health institutions, including the WHO, the Centers for Disease Control and Prevention, the American Academy of Pediatrics and the WHO-established Vaccine Safety Net, “a global network of websites providing reliable vaccine safety information.” Moreover, it won’t show comments, recommendations or ads, so this is not just a case of displaying correct information next to the dodgy, but rather a genuine effort to present authoritative data to its 300 million monthly users.

The principle here is worthy: With free speech comes responsibility, in this case, to not spread misinformation that can lead to illness and death. Other social media platforms are also acting against anti-vaccination information, but Pinterest is bolder and should be emulated.

As both the Ebola and polio inoculation campaigns have shown lately, having an effective vaccine is only part of the battle. Populations must trust the vaccine and those who administer it. Social media should not provide a stage for misguided people to destroy that trust, and digital platforms can do much to help rebuild it.

News: Global public meeting on draft ICH guideline on clinical trials

Milestones :: Perspectives :: Research

 

News: Global public meeting on draft ICH guideline on clinical trials
News 30/08/2019 European Medicines Agency
The global guidance for the conduct of clinical trials is currently undergoing a major revision. As part of the worldwide consultation process, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is organising a public meeting to review its draft E8 (R1) Guideline ‘General Considerations for Clinical Trials’. EMA is encouraging its stakeholders to register for this meeting, which will be held on 31 October 2019 at the United States Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland, United States of America. Participants will be able to attend in person or via webcast.

The ICH E8 guideline sets out general scientific principles for the conduct, performance and control of clinical trials. In recent years, clinical trials have undergone a radical transformation with a wider range of both trial designs and data sources being used in drug development. Therefore, ICH initiated a revision of the E8 guideline to address all the aspects that were not covered by the current version of the guidance.

The revision aims to provide up-to-date and flexible guidance on clinical trial designs and data sources that can support regulatory and other health-policy decisions while ensuring that fundamental principles, such as the protection of clinical trial participants and assurance of data quality, are maintained.

This is the first step outlined in the process of renovation of good clinical practice (GCP), described in the ICH reflection paper on GCP “Renovation”. The reflection paper contains the ICH proposal for further modernisation of the ICH guidelines related to clinical trial design, planning, management, and conduct. The scope of the proposed renovation includes the current E8 guideline and further revision to the E6 Guideline for Good Clinical Practice.

The draft revised E8 guideline was released for public consultation in May 2019 and it will remain open until 30 September 2019.

The purpose of the public meeting is to provide information and gather feedback from a broad range of stakeholder groups not represented in ICH. The viewpoints and concerns expressed by external stakeholders will feed into the revision process of this fundamental guideline.

The meeting will be held on 31 October 2019, 8:30 – 18:00, at the FDA headquarters in Silver Spring, Maryland, USA. Participants can register to attend in person or via webcast, on a first-come, first-served basis. More information, including on how to register, is available on the ICH website

Featured Journal Content

Featured Journal Content

 

Epidemics
Volume 28 September 2019
https://www.sciencedirect.com/journal/epidemics/vol/28/suppl/C
Research article Open access
Real-time predictions of the 2018–2019 Ebola virus disease outbreak in the Democratic Republic of the Congo using Hawkes point process models
J. Daniel Kelly, Junhyung Park, Ryan J. Harrigan, Nicole A. Hoff, … Frederic Paik Schoenberg
Article 100354
Highlights
:: Current 2018–2019 Ebola outbreak in DRC is the second largest ever with over 1600 cases as of 10 May 2019.
:: Evidence of an increase in the estimated transmission rates in health zones with recently reported violence versus those without (p = 0.008) in time series analysis.
:: The average R was estimated as between 0.61 and 0.86 in regions not affected by recent violence.
:: Estimated the increase in R between 0.17 and 0.53.
:: Violence is contributing to the continued transmission and the ongoing nature of this outbreak.